ASCOR

Peak

ascorbic acid

NDAINTRAVENOUSSOLUTION
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11

Mechanism of Action

12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The exact mechanism of action of ascorbic acid for the treatment of symptoms and signs of scurvy (a disorder caused by severe deficiency in vitamin C) is unknown; however, administration of ascorbic acid in patients with scurvy is thought to…

Pharmacologic Class:

Vitamin C

Indications (2)

vitamin C deficiencysymptoms of scurvy

Clinical Trials (5)

NCT05501548Phase 2Terminated

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Started Jun 2023
4 enrolled
Prostate CancerCastration-resistant Prostate Cancer
NCT03697239Phase 1/2Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started Jun 2019
0
Metastatic Pancreatic CancerPancreatic CancerPancreas Cancer+3 more
NCT03908333Phase 1/2Withdrawn

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started May 2019
0
Metastatic Pancreatic CancerPancreatic CancerPancreas Cancer+3 more
NCT03797443Phase 1/2Withdrawn

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Started Jan 2019
0
Metastatic Pancreatic Cancer
NCT03334409Phase 2Terminated

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Started Feb 2018
5 enrolled
Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+2 more
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers